Reported Late Monday, MediciNova Receives A Notice Of Allowance For A New Patent Covering MN-001 And MN-002 For The Treatment Of Hypertriglyceridemia, Hypercholesterolemia, and Hyperlipoproteinemia In Brazil
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced it has received a Notice of Allowance